Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while State Street Real Estate Select Sector SPDR ETF trades at $41.8 (market cap $7.83B). The key difference: Spyre Therapeutics Inc. Common Stock and State Street Real Estate Select Sector SPDR ETF are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and State Street Real Estate Select Sector SPDR ETF for 77 Days on average.
| SYRE | XLRE | |
|---|---|---|
Market Cap | $7.52B | $7.83B |
Volume | 1,441,031 | 5,853,296 |
Sector | Health | Sector/Thematic |
52-Week High | $108.92 | $46.01 |
52-Week Low | $22.18 | $40.01 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.83, down 0.21% on the day. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Key financial ratios are not available in the provided data. Recent news highlights the fund's low expense ratio of 0.08% and its focus on 30 U.S. large-cap real estate holdings, positioning it as a cost-effective domestic real estate exposure tool.
The outlook for XLRE is influenced by competing factors: its low-cost structure is a strength, but the sector faces headwinds from rising bond yields and potential interest rate volatility. Investment opportunity lies in its role as a pure-play U.S. real estate ETF, while risks include macroeconomic sensitivity and competition from more diversified or thematic real estate funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
